Key facts
- It has raised $1.4M; the latest was Angel (individual) ($1.2M) in Jun 2025.
- Notable investors include Venture Kick, Berlin Angel Fund, Business Angels Club Berlin-Brandenburg, Fongit, University of Geneva.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for KYLYS
- ·The full record, as it builds
Funding rounds
No funding rounds for KYLYS are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About KYLYS
Developer of biomolecule-based products designed to fulfill medical, surgical, and cosmetic needs. The company offers hyaluronic acid pearls which are new biocompatible and biodegradable gels that are easily injectable as a fluid gel at room temperature, can form in the tissue, at body temperature, and microgel structures providing durable effect and absence of migration from the injection site, enabling healthcare providers to offer their patients with effective and safe products.
- Sector
- Healthcare
- HQ
- Plan-les-Ouates, Switzerland
- Founded
- 2017
- Employees
- 3
- Website
- kylys.com/
- Ownership
- Privately Held (backing)
KYLYS doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in KYLYS shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on KYLYS in its N-PORT filings yet. We sweep new filings monthly.